Mustang Favorable Efficacy, Safety Data from Waldenstrom Macroglobulinemia Phase 1/2

 Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months

All patients were heavily pretreated/refractory to BTK inhibitors, and only one patient has started new anti-WM treatment after MB-106

Outpatient administration was allowed and found to be feasible

Currently no FDA-approved CAR-T treatments for WM

Data presented at the European Hematology Association 2024 Hybrid Congress

https://www.globenewswire.com/news-release/2024/06/17/2899667/0/en/Mustang-Bio-Announces-Favorable-Efficacy-and-Safety-Data-from-Complete-Waldenstrom-Macroglobulinemia-Cohort-of-Phase-1-2-Clinical-Trial-of-MB-106-CD20-Targeted-Autologous-CAR-T-The.html